Skip to main content

Boston Scientific Chief Financial Officer, Lawrence C. Best, Joins Archemix Corp. Board of Directors – Archemix

Boston Scientific Chief Financial Officer, Lawrence C. Best, Joins Archemix Corp. Board of Directors

Boston Scientific Chief Financial Officer, Lawrence C. Best,

Joins Archemix Corp. Board of Directors

 CAMBRIDGE, MA April 26, 2005 Archemix Corp., the privately-held

biopharmaceutical company focused on discovering and developing aptamer-based

therapeutics, announced today that Lawrence C. Best has been appointed to the

Companys Board of Directors.  In addition to his responsibilities as a

Board member, Mr. Best qualifies as an Audit Committee Financial Expert in

accordance with Regulation S-K 401(h) and the rules implementing Section 407 of

the Sarbanes-Oxley Act.

Mr. Best currently serves as Executive

Vice President and Chief Financial Officer of Boston Scientific Corporation. He

brings more than 30 years of financial experience to Archemix.  Prior to

his work with Boston Scientific, Mr. Best was a partner in the accounting firm

of Ernst & Young, where he specialized in serving multinational companies in

the high technology and life sciences fields. He served a two-year fellowship at

the Securities and Exchange Commission from 1979 to 1981 and a one-year term as

a White House-appointed Presidential Exchange Executive in Washington. Mr. Best is also a Director and Audit

Committee Financial Expert for Biogen Idec and Haemonetics Corporation.

We are

privileged to have someone of Larrys experience and knowledge join our Board,

commented Dr. Errol De Souza, Chief Executive Officer of Archemix. “Larry brings

an impressive record of financial expertise and strategic management and has

been a key member of the Boston Scientific executive team that is credited with

building one of the foremost companies in the medical device industry.

Dr. De Souza also stated that filling the role of financial expert is an

important step for Archemix as we continue to evolve our Board to meet the

requirements of a public company.

Archemix is at an exciting stage of its development,

said Mr. Best. The Companys aptamers have the potential to bring forth a new

class of therapeutics for the treatment of acute and chronic diseases. I look

forward to contributing to Archemix as the company strives to meet its strategic

initiatives and develops its portfolio of aptamer therapeutics.

About Aptamers


are single-stranded nucleic acids that form well-defined three-dimensional

shapes, allowing them to bind to target molecules in a manner that is

conceptually similar to antibodies. Aptamers combine the optimal characteristics

of small molecules and antibodies, including high specificity and affinity,

chemical and biological stability, low toxicity and immunogenicity and the

ability to target protein-protein interactions. In contrast to monoclonal

antibodies, aptamers are chemically synthesized rather than biologically

expressed, offering a significant cost advantage. As therapeutic agents,

aptamers have demonstrated clinical biological efficacy and have excellent,

tunable pharmacokinetic properties.

About Archemix



Corp. is a privately-held biopharmaceutical company based in

Cambridge, Massachusetts. The company’s

mission is to develop aptamers as a class of directed therapeutics for the

treatment of human disease. Because of their unique properties and proven

efficacy, aptamers are a superior alternative to biologics and small molecules

and will be a major class of drugs for the treatment of unmet medical needs.

Archemix’s aptamer expertise is complemented by a

dominant patent estate comprised of over 220 issued and 230 pending patents

covering the identification, composition and use of therapeutic aptamers. In

addition to the company’s core aptamer generation technology, Archemix possesses

strong expertise in both preclinical and clinical drug development. Further

information about Archemix can be found at